Werewolf Therapeutics
HOWL
36 hedge funds and large institutions have $73.3M invested in Werewolf Therapeutics in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 10 increasing their positions, 3 reducing their positions, and 3 closing their positions.
233% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 3
17% more capital invested
Capital invested by funds: $62.5M → $73.3M (+$10.8M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.48% less ownership
Funds ownership: 68% → 67.52% (-0.48%)
3% less funds holding
Funds holding: 37 → 36 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
91% less call options, than puts
Call options by funds: $1K | Put options by funds: $11K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SSA
Schonfeld Strategic Advisors
New York
|
+$713K |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$244K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$99.9K |
| 4 |
BlackRock
New York
|
+$98.5K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$31.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$670K |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$314K |
| 3 |
B
Bailard
Foster City,
California
|
-$47.1K |
| 4 |
Two Sigma Investments
New York
|
-$26.2K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$4.53K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Two Sigma Investments
New York
| $50.4K | -$26.2K | -9,300 | -36% |
|
|
TRCT
27
Tower Research Capital (TRC)
New York
| $8.62K | +$3.67K | +1,303 | +85% |
|
28
Morgan Stanley
New York
| $7.63K | – | – | – |
|
29
Fidelity Investments
Boston,
Massachusetts
| $6.41K | – | – | – |
|
|
FP
30
Financial Perspectives
Minneapolis,
Minnesota
| $3.81K | – | – | – |
|
31
UBS Group
Zurich,
Switzerland
| $3.05K | – | – | – |
|
32
JP Morgan Chase
New York
| $2.28K | – | – | – |
|
33
Simplex Trading
Chicago,
Illinois
| $1K | +$1.77K | +629 | New |
|
34
Wells Fargo
San Francisco,
California
| $415 | +$113 | +40 | +42% |
|
|
GIA
35
GHP Investment Advisors
Denver,
Colorado
| $209 | +$225 | +80 | New |
|
|
GWS
36
Glassman Wealth Services
Vienna,
Virginia
| $15 | – | – | – |
|
|
37
Marshall Wace
London,
United Kingdom
| – | -$314K | -120,936 | Closed |
|
|
B
38
Bailard
Foster City,
California
| – | -$47.1K | -18,127 | Closed |
|
HOWL Hedge Fund Activity: Q2 2023 in Review
36 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Werewolf Therapeutics (HOWL) for Q2 2023, worth a combined $73.3M — up 17% from $62.5M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of HOWL and 2 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 10 added.
The largest buyer was Schonfeld Strategic Advisors, adding an estimated $713K. The largest seller was Millennium Management, cutting an estimated $670K.
- 36 institutional investors held Werewolf Therapeutics (HOWL) as of Q2 2023, down from 37 in Q1 2023.
- Funds reported $73.3M of Werewolf Therapeutics stock for Q2 2023, up 17% quarter-over-quarter.
- 2 funds opened new Werewolf Therapeutics positions in Q2 2023 and 3 closed out, a net change of -1 holder.
- The largest Werewolf Therapeutics buyer in Q2 2023 was Schonfeld Strategic Advisors, an estimated $713K added.
- The largest Werewolf Therapeutics seller in Q2 2023 was Millennium Management, an estimated $670K sold.
Based on aggregated 13F filings for Q2 2023.